Results 191 to 200 of about 235,727 (237)

Chagas Cardiomyopathy in Latin America Review

Current Cardiology Reports, 2019
Chagas cardiomyopathy is a major public health disease in Latin America and, due to migration, is becoming a worldwide health and economic burden. This review sought to present the clinical and epidemiological aspects of Chagas cardiomyopathy, as well as some specific features and principles of treatment.
Jefferson Luis, Vieira, Fábio Rocha Fernandes, Távora, Maria Gyslane Vasconcelos, Sobral, Glauber Gean, Vasconcelos, Germana Porto Linhares, Almeida, Juliana Rolim, Fernandes, Laura Leite, da Escóssia Marinho, Daniel Francisco, de Mendonça Trompieri, João David, De Souza Neto, Juan Alberto Cosquillo, Mejia   +9 more
openaire   +3 more sources

Chagas Disease Cardiomyopathy

Dimensions of Critical Care Nursing, 2023
Abstract Chagas disease is a prominent neglected tropical disease endemic to many countries in Latin America. Cardiomyopathy is the most serious manifestation due to the severity and complications of heart failure. As a result of expanded immigration and globalization, there is an increased number of patients with Chagas cardiomyopathy who are being ...
Ariana, Jimenez, Elizabeth J, Winokur
openaire   +2 more sources

Chagas cardiomyopathy and captopril

European Heart Journal, 1992
Chagas disease is a leading cause of heart failure in Latin America. Sudden death occurs in approximately 40% of patients with heart failure due to Chagas disease. We report a single blind, cross-over trial of prolonged treatment with captopril and placebo in 18 Chagas disease patients with class IV NYHA heart failure.
Roberti, Roberto Rinaldo UNIFESP, Martinez, E. E., Andrade, José Lazaro de UNIFESP, Araujo, V. L., Brito, Flavio Souza UNIFESP, Portugal, Oscar Pimentel UNIFESP, Horowitz, S. F.   +6 more
openaire   +3 more sources

Heart transplantation for chagas' cardiomyopathy

The Annals of Thoracic Surgery, 1995
We present 2 patients who underwent orthotopic heart transplantation for end-stage Chagas' cardiomyopathy. Despite immunosuppressive therapy, postoperative prophylaxis with nifurtimox appeared to prevent Trypanosoma cruzi reactivation. Neither patient has shown signs of Chagas' myocarditis, and both are clinically well 12 and 72 months after ...
C, Blanche, I, Aleksic, J J, Takkenberg, L S, Czer, M C, Fishbein, A, Trento   +5 more
openaire   +2 more sources

Echocardiographic parameters, speckle tracking, and brain natriuretic peptide levels as indicators of progression of indeterminate stage to Chagas cardiomyopathy

Echocardiography, 2020
Chronic Chagas cardiomyopathy (CCM) is characterized by a unique type of cardiac involvement. Few studies have characterized echocardiographic (Echo) transitions from the indeterminate Chagas disease (ChD) form to CCM.
L. E. Echeverría, L. Z. Rojas, M. C. Villamizar, C. Luengas, Angel M Chaves, Jaime A Rodríguez, Rafael Campo, Claudia F. Clavijo, Adriana M Redondo, Luis A. López, S. A. Gómez-Ochoa, C. Morillo, O. Rueda-Ochoa, O. Franco   +13 more
semanticscholar   +1 more source

Survival after heart transplantation for Chagas cardiomyopathy using a conventional protocol: A 10‐year experience in a single center

Transplant Infectious Disease, 2020
Heart transplant (HT) remains the most frequently indicated therapy for patients with end‐stage heart failure that improves prognosis in Chagas cardiomyopathy (CCM).
L. E. Echeverría, A. Figueredo, M. J. Rodríguez, L. Salazar, C. Pizarro, C. Morillo, L. Z. Rojas, S. A. Gómez-Ochoa, Víctor R Castillo   +8 more
semanticscholar   +1 more source

Effects of Trypanocidal Treatment on Echocardiographic Parameters in Chagas Cardiomyopathy and Prognostic Value of Wall Motion Score Index: A BENEFIT Trial Echocardiographic Substudy

Journal of the American Society of Echocardiography, 2019
Background: Serial echocardiographic studies in chronic Chagas cardiomyopathy are scarce. The aims of this study were to evaluate whether therapy with benznidazole modifies the progression of cardiac impairment and to identify baseline echocardiographic ...
A. Schmidt, M. Romano, J. Marin-Neto, P. Rao-Melacini, A. Rassi, A. Mattos, Á. Avezum, Erick Villena, S. Sosa-Estani, Rina Bonilla, S. Yusuf, C. Morillo, B. Maciel   +12 more
semanticscholar   +1 more source

Chagas' cardiomyopathy and Lyme carditis: Lessons learned from two infectious diseases affecting the heart.

Trends in cardiovascular medicine, 2020
Chagas' disease and Lyme disease are two endemic, vector-borne zoonotic infectious diseases that impact multiple organ systems, including the heart. Chagas' cardiomyopathy is a progressive process that can evolve into a dilated cardiomyopathy and heart ...
C. Yeung, I. Mendoza, L. E. Echeverría, A. Baranchuk   +3 more
semanticscholar   +1 more source

Chagas cardiomyopathy and ischemic stroke

Expert Review of Cardiovascular Therapy, 2006
American trypanosomiasis, known as Chagas disease is a major cause of cardiomyopathy in South America. Irreversible damage to the heart can appear 10-20 years after chagasic infection. The relationship between Chagas cardiomyopathy and ischemic stroke has been reviewed.
openaire   +2 more sources

Clinical management of chronic Chagas cardiomyopathy

Frontiers in Bioscience, 2003
Chagas disease is caused by a protozoan parasite, Trypanosoma cruzi, and infects over 15 million people worldwide. New cases of the disease are now uncommon, mainly due to national control programs in Latin America. However, there is a large reservoir of chronically infected patients, many of whom will develop chagasic cardiopathy.
Manoel O C, Rocha, Antonio Luiz P, Ribeiro, Mauro M, Teixeira   +2 more
openaire   +2 more sources